Angiotensin Type 1 Receptor Autoantibody in Wound Healing

Case ID:
C13817
Disclosure Date:
9/15/2015

Unmet Need:

Chronic wounds are among the most common, painful, debilitating and costly conditions in diabetics and in older adults, and are an important portal for bacterial infections that often lead to amputations, sepsis and mortality. In diabetic and aging skin, chronic inflammation commonly accompanies poor wound healing and increases the risk for chronic non healing wounds. In diabetic and aged skin, the angiotensin system is dysregulated with aberrant angiotensin AT1 receptors (AT1R) signaling that increases inflammatory burden leading to thinning of epidermis, degeneration of collagen, fracture of dermal layer, and atrophy of subcutaneous fat. The reason for the activation of the angiotensin receptors is not known, but stimulatory AT1R autoantibodies (AT1RaAb) increase AT1R signaling, and likely thereby impair wound healing by irreversibly activating AT1R.


Technology Overview:

JHU investigators have developed a topical Angiotensin Receptor blocker treatment that effectively treats chronic wounds in preclinical studies, but the effects of this topical treatment with angiotensin receptor blockers (ARBs) in older individuals may depend on levels of AT1RaAb since AT1RaAb may compete with ARBs for receptor occupancy. This technology is aimed at specifically determining the levels of these autoantibodies in older and diabetic patients with chronic wounds. It utilizes the level of the antibody as a serum biomarker to identify a subset group of patients with elevated AT1RaAb associated with chronically delayed wound healing that will likely respond to topical treatment with angiotensin receptor blockers.


U.S. Patent No. 10,648,977 and pending US application US 2020/0264173




Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Angiotensin Type 1 Receptor Autoantibody in Wound Healing PCT: Patent Cooperation Treaty PCT PCT/US2016/059363   10/28/2016     Expired
ANGIOTENSIN RECEPTOR AUTOANTIBODIES AS BIOMARKER FOR EFFECTIVE USAGE OF ANGIOTENSIN RECEPTOR BLOCKERS PCT: Patent Cooperation Treaty United States 15/769,617 10,648,977 4/19/2018 5/12/2020 10/30/2036 Granted
ANGIOTENSIN RECEPTOR AUTOANTIBODIES AS BIOMARKER FOR EFFECTIVE USAGE OF ANGIOTENSIN RECEPTOR BLOCKERS CON: Continuation United States 17/458,613   8/27/2021     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum